Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Daily Record
Daily Record
National
Melanie Bonn

Perth's Lily Douglas starts new cancer drug trial in Newcastle

Newcastle’s Great North Children’s Hospital got a special delivery from Perth on Monday - 14-year-old Lily Douglas arrived with her mum to start a new drug treatment hoped to fight her cancer.

Taking part in a new drug trial, Lily is believed to be the first child in the world to receive the potential breakthrough treatment.

Lily's gone to look for help at one of the UK's major children's centres of medicine.

Pictured looking every bit like a Christmas angel, Lily smiled from the reception of RVI Children's Outpatients in Newcastle upon Tyne.

On December 13 her mum Jane updated the many thousand Facebook followers who care deeply about Lily’s battle with Ewing sarcoma and posted: “We have arrived in Newcastle for Lily’s new trial.

“She has a week of tests/bloods/heart scans/operation and body scans. All going well, she starts her new drug on Monday, December 20.

“We have to stay to see how she is doing as Lily will be THE FIRST CHILD IN THE WORLD TO GET THIS DRUG.

“We’re not sure if we will get home to Perth for Christmas as she will need to be closely monitored.

“This is obviously very nerve-racking for us but Lily is very poorly and needs to get on treatment asap.

“We are blessed the NHS really are amazing and the team here are brilliant.

“We will try to make the best of it and I am sure we will get to see the lovely sights of Newcastle as we will be here loads.”

Lily has been bravely accepting operations and cancer treatments since she was nine years old.

Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.